ACC: Losmapimod Doesn't Cut Cardio Events After Acute MI

This article originally appeared here.
Share this content:
ACC: Losmapimod Doesn't Cut Cardio Events After Acute MI
ACC: Losmapimod Doesn't Cut Cardio Events After Acute MI

MONDAY, April 4, 2016 (HealthDay News) -- For patients with acute myocardial infarction, use of losmapimod does not reduce major ischemic cardiovascular events compared with placebo, according to a study published online April 4 in the Journal of the American Medical Association. The research is being published to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Chicago.

Michelle L. O'Donoghue, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues examined the efficacy and safety of losmapimod on cardiovascular outcomes in the LATITUDE-TIMI 60 trial involving patients hospitalized with acute myocardial infarction. A leading cohort (3,503 participants) was used to provide an initial assessment of safety and exploratory efficacy; participants were randomized to treatment with twice-daily losmapimod (1,738 patients) or matching placebo (1,765 patients) for 12 weeks.

Overall, 99.1 percent of the patients had complete ascertainment for the primary outcome (a composite of cardiovascular death, myocardial infarction, or severe recurrent ischemia). The researchers found that by 12 weeks, the primary outcome had occurred in 7.0 percent of those treated with placebo and in 8.1 percent of those treated with losmapimod (hazard ratio, 1.16; 95 percent confidence interval, 0.91 to 1.47). The on-treatment rates of serious adverse events were 16.0 and 14.2 percent with losmapimod and placebo, respectively.

"The results of this exploratory efficacy study did not justify proceeding to a larger efficacy trial in the existing patient population," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures losmapimod and funded the LATITUDE-TIMI 60 trial.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Both Statin, Non-Statin Therapies Effective for Lowering LDL

Both Statin, Non-Statin Therapies Effective for Lowering LDL

Dietary changes, other meds, and even surgery can lower cardiovascular risk similarly to statins

Negative Effects Seen With Video Gaming 9 Hours/Week

Negative Effects Seen With Video Gaming 9+ Hours/Week

Benefits seen with one hour a week, but behavioral problems appear to rise at nine hours a week

Improved Adult Lung Function Linked to Childhood Farm Life

Improved Adult Lung Function Linked to Childhood Farm ...

First study to report beneficial effects of growing up on a farm on adult FEV1

is free, fast, and customized just for you!

Already a member?

Sign In Now »